News
Asarina Pharma obtains convertible loan for continued research on neurological conditions including Obsessive Compulsive Disorder
2021-05-31 18:00
The convertible loan supplements Asarina Pharma’s current financial resources and will be spent on further exploration of the potential of Sepranolone...
Asarina Pharma: Issuance of 700,000 warrants completed
2021-05-28 08:20
Each warrant gives the holder the right to subscribe to one new Asarina share at a fixed price of SEK 9.87 (150% of the average share price during the...
Asarina Pharma receives approval of CTA for phase IIa Tourette study
2021-05-19 08:00
With Cognitive Behavioral Therapy as first-line treatment for Tourette, and many pharma treatments exhibiting severe side effects, there is a large unmet...
Asarina Pharma AB (publ) Q1 Report 2021 released
2021-05-18 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME For further information, please contact: Peter Nordkild, CEO Phone: +45 25...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
2021-04-21 11:00
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2020...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)
2021-03-22 17:00
Due to the extraordinary situation resulting from the covid-19 pandemic, the Company encourages shareholders to exercise their voting rights at the AGM...
Asarina Pharma AB (publ) Annual Report 2020 released
2021-03-15 19:40
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME (TS) MENSTRUAL MIGRAINE (MM) PREMENSTRUAL DYSPHORIC DISORDER (PMDD) For further information...
Asarina Pharma AB (publ) Q4 / Year End 2020 report released
2021-02-25 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME For further information, please contact: Peter Nordkild, CEO Phone: +45 25...
New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
2021-02-11 18:32
Professor Marco Bortolato presented the new preclinical findings at the “Allopregnanolone and its synthetic analogues: from bench to clinical strategies...
Asarina Pharma AB (publ) Q3 2020 report released
2020-11-25 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS For further information, please contact: Peter Nordkild, CEO Phone: +45 25 47 16 46 E-mail: peter.nordkild@asarinapharma.com...